ArticleNature communications2023
Towards evidence-based response criteria for cancer immunotherapy.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- What are RECIST 1.1 progressions made of? Variability in double-read oncology trials.European radiology · 2026Article
- Immune Checkpoint Inhibitors Beyond Progression in Various Solid Tumors: A Systematic Review and Pooled Analysis.Journal of clinical medicine · 2025Review
- A Multi-marker model based on serum IL-10 predicts response to conversion immunochemotherapy in gastric cancer patients: a retrospective cohort study.BMC gastroenterology · 2025Article
- Dual-energy CT iodine concentration as a biomarker for immunotherapy treatment response in metastatic melanoma and renal cell carcinoma patients.European radiology · 2025Article
- Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study.Cancer research communications · 2025Article
- Efficacy assessment in phase I clinical trials: endpoints and challenges.Annals of oncology : official journal of the European Society for Medical Oncology · 2025Review
- Evaluating the impact of doxorubicin preconditioning on the efficacy of inhaled recombinant human IL-15 immunotherapy in dogs with pulmonary metastasis.Veterinary oncology (London, England) · 2025Article
- Standardized Response Assessment in Patients with Advanced Cholangiocarcinoma Treated with Personalized Therapy.Journal of personalized medicine · 2024Article
- Artificial intelligence in immunotherapy PET/SPECT imaging.European radiology · 2024Review
- The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.Endocrine reviews · 2024Review
- A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking?NPJ precision oncology · 2024Review
- Precision USPIO-PEG-SLeInternational journal of nanomedicine · 2024Article
- PD-1/PD-L1 Inhibitor - Related Adverse Events and Their Management in Breast Cancer.Journal of Cancer · 2024Review
- Advancements in dendritic cell vaccination: enhancing efficacy and optimizing combinatorial strategies for the treatment of glioblastoma.Frontiers in neurology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.